跳至主要内容
临床试验/NCT05333692
NCT05333692已完成不适用

Oral Nutritional Supplementation of Hemodialysis Patients

Fresenius Kabi Taiwan Ltd.2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2020年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90
试验地点
2
主要终点
Serum Albumin level change

研究概览

简要总结

This study is aimed to demonstrate that increase in serum albumin concentration (week 8 -baseline) after test treatment (Fresubin® Protein Energy DRINK), a standard ONS, is not relevantly smaller than that after control treatment with NEPRO®.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 40-80 years
  • Acute or chronic renal failure patients who need dialysis and already dialysis for 3 months at least.
  • Malnutrition patients. Definition of Malnutrition is serum albumin level<3.5g/dL, calorie digestion below 35kcal/IBW or protein digestion below 1.2g/IBW.

排除标准

  • BMI<18.5 and calorie intake unable to reach 50% of the recommended level
  • BMI>30 kg/m2,
  • abnormal liver function,
  • malignant disease,
  • scheduled surgery within a month or after surgery,
  • infectious disease,
  • suboptimal tolerance of nutritional supplements,
  • inflammatory bowel disease, bowel obstruction,
  • acute condition complicated with multiple organ failure or under palliative care.

结局指标

主要结局

Serum Albumin level change

时间窗: baseline, weerk 4 and week 8

次要结局

  • Body Weight (kg) and Height(cm) change, and these results will be combine to report BMI (kg/m^2) change(baseline, weerk 4 and week 8)

研究者

发起方
Fresenius Kabi Taiwan Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验